CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Despite my optimism about the long-term prospects of curative gene therapy and CRISPR Therapeutics (NASDAQ:CRSP) stock, a sense of pragmatism and potentially a reality check are in order. Noting the ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...

CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for ...